• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Oakwood Laboratories L.L.C. - Product Pipeline Review - Q4 2010 - Product Image

Oakwood Laboratories L.L.C. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 27 pages
  • Global Markets Direct

Oakwood Laboratories L.L.C. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Oakwood Laboratories L.L.C. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oakwood Laboratories L.L.C. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oakwood Laboratories L.L.C. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Oakwood Laboratories L.L.C. Snapshot
Oakwood Laboratories L.L.C. Overview
Key Information
Key Facts
Oakwood Laboratories L.L.C. – Research and Development Overview
Key Therapeutic Areas
Oakwood Laboratories L.L.C. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Oakwood Laboratories L.L.C. – Pipeline Products Glance
Oakwood Laboratories L.L.C. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Oakwood Laboratories L.L.C.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Oakwood Laboratories L.L.C. – Drug Profiles
Leuprolide 22.5 mg
Product Description
Mechanism of Action
R&D Progress
Leuprolide 7.5 mg
Product Description
Mechanism of Action
R&D Progress
Dermal Fill
Product Description
Mechanism of Action
R&D Progress
Leuprolide 3.75 mg
Product Description
Mechanism of Action
R&D Progress
Leuprolide 30 mg
Product Description
Mechanism of Action
R&D Progress
Leuprolide 45 mg
Product Description
Mechanism of Action
R&D Progress
Octreotide
Product Description
Mechanism of Action
R&D Progress
Risperidone
Product Description
Mechanism of Action
R&D Progress
Oakwood Laboratories L.L.C. – Pipeline Analysis
Oakwood Laboratories L.L.C. – Pipeline Products by Therapeutic Class
Oakwood Laboratories L.L.C. Pipeline Products By Target
Oakwood Laboratories L.L.C. – Pipeline Products by Molecule Type
Oakwood Laboratories L.L.C. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Oakwood Laboratories L.L.C., Deals Summary, 2004 to 2010
Oakwood Laboratories L.L.C. Detailed Deal Summary
Licensing Agreements
Oakwood Laboratories Enters Into Licensing Agreement With Santen Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS